NICE says yes to new hepatitis C drug from Merck & Co

9 September 2016

In draft guidance issued today, the National Institute for Health and Care Excellence (NICE) is recommending Zepatier (elbasvir-grazoprevir) as an option to treat certain types of hepatitis C.

Elbasvir-grazoprevir, developed by US pharma giant Merck & Co (NYSE: MRK) which trades in the UK as Merck Sharp & Dohme (MSD), is used to treat chronic hepatitis C in adults with genotypes 1a, 1b or 4. It works by blocking two proteins that cause the virus to multiply and infect new cells,noted the medicines cost-effectiveness watchdog for England and Wales.

In trials, elbasvir-grazoprevir had cure rates above 90% for people with hepatitis C genotypes 1 and 4. The cure rate of the drug depends on the genotype, treatment history and presence of liver damage. As elbasvir-grazoprevir was just as effective as similar treatments that are already available, the NICE appraisal committee concluded that it should be routinely available on the National Health Service.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK